Myasthenia gravis (MG) is a rare, chronic neuromuscular autoimmune disease with a median global prevalence of 10 per 100,000 and an in-hospital mortality rate of 1.8%. The hallmark of MG pathology is ...

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug, telitacicept (RCT-18; Tai’ai), in the ...

Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG and likely not in need v of a respirator for the duration of the study, as judged by the Investigator. * The confirmation of the ...

Carte­sian Ther­a­peu­tics said its au­tol­o­gous CAR-T ther­a­py has shown “sus­tained ben­e­fits” in peo­ple with a rare au­toim­mune dis­ease, ac­cord­ing to the lat­est ...

RNAC on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized myasthenia gravis (MG).

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 ...

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 weeks ...

Credit: Getty Images In a phase 3 clinical trial, researchers assessed the efficacy and safety of inebilizumab in patients with generalized myasthenia gravis. At Week 26, compared to the placebo ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

1 Antozzi, C et al., Long-Term Safety and Efficacy of Nipocalimab in Generalized Myasthenia Gravis: Vivacity-MG3 Open-Label Extension Phase Results. Abstract #022 for poster presentation at 2025 ...